Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (August 2023)
19 slides from Enveric Biosciences's investor presentation, Aug 25, 2023
Slide 1: Corporate Presentation Q3 2023
:ENVB CORPORATE PRESENTATION Q3 2023 Enveric.com
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: Next Generation Mental Health
Next Generation TM Mental Health
Slide 4: Mental Health Epidemic
Mental Health Epidemic WIDESPREAD HIGH DISABILITY 1 in 4 experiences a mental illness in any Mental illness and substance use given year disorders are the leading causes of disability LOW EFFICACY DIMINISHED LONGEVITY People with severe mental health 40% conditions die First line SSRIs treatments wo
Slide 5: Neuroplastogens: A New Class of Drugs
Neuroplastogens: A new Class of Drugs Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala. Neuroplastogens stimulate Neuropsychiatric Illness: Reduced neural neuroplasticity in the PFC, which restores This modulates
Slide 6: Our Portfolio of Neuroplastogen Molecules
Our Portfolio of Neuroplastogen Molecules • The PsybraryTM : Our library of 500+ potential neuroplastogen drug candidates F E G • We combined synthetic biology HO D H and chemistry technologies to C I J create a highly diverse portfolio for B drug discovery K A • Molecules are designed based on SERO
Slide 7: Distinct Neuroplastogen Treatment Paradigms
Distinct Neuroplastogen Treatment Paradigms In Clinic Prescription Model • High dose • Moderate dose • Clinical setting • Prescription model • One course of therapy potentially • Taken regularly provides benefit for months • Minimal side effects and reduced • Treatment is associated with hallucinati
Slide 8: Pipeline Programs
Pipeline Programs PROGRAM INDICATION PERFORMANCE GOALS DISCOVERY PRE-CLINICAL PHASE I NEXT MILESTONE 5HT2AR ligand, Brain- In Clinic: Anxiety targeted, Faster-acting, EB-373 Shorter duration, Reduced Initiate FIH in Australia GI upset 5HT2AR ligand, Sub-clinical Prescription: Anxiety, /non-hallucino
Slide 9: In Clinic Program: EB-373
In Clinic Program: EB-373 Synopsis of Target Benefits • Altered metabolic and pharmacokinetic properties relative to psilocybin to achieve improved risk/benefit profile • Flexible delivery route – potential for oral, intra-nasal, buccal or intravenous route for ⚬ Faster access to target receptor and
Slide 10: EB-373 Development
EB-373 Development Developed an improved Established Enveric Agreement with Positive results from Completed in-vitro formulation of EB-373 Therapeutics Pty. Ltd., an Avance Clinical, an animal studies metabolism designed to enhance the Australia-based Australia-based CRO, demonstrating oral studies
Slide 11: Anxiety Market: New Treatments Needed
Anxiety Market: New $16.3 B Market Treatments Needed USD Market • Anxiety disorders are among the most common CNS Disorders, by 2029 Source: Data Bridge ranking second. • Anxiety disorders are chronic conditions that remain poorly controlled despite available treatments. Percent of Adults Ages 18-64
Slide 12: Prescription Model Program: EVM301
Prescription Model Program: EVM301 Synopsis of Target Benefits • Reduced hallucination profile • Improved cardiac safety • Orally bioavailable, chronic administration • Treatment in clinic not required • Drug intended to be prescribed for regular maintenance and taken at times and in settings more c
Slide 13: Neuropsychiatric Market Rapidly Growing
Neuropsychiatric Market The global behavioral Market drug market size is Rapidly Growing expected to reach • Neuropsychiatric disorders continue to be a tremendous unmet need with limited innovation. • The last FDA-approved drug to treat Neurpsychiatric disorders was Esketamine (2019) and $58.9 B by
Slide 14: Intellectual Property
Intellectual Property PsybraryTM: Portfolio of 500+ drug candidates Patents ⚬ EB-373: ⚬ US Patent 11,707,447 and two more US and PCT applications – compositions of numerous molecules ⚬ Prodrug molecules other than EB-373 ⚬ One US Notice of Allowance, nine more US and six PCT applications – compositi
Slide 15: Potential for Strategic Drug Development Deals
Potential for Strategic Drug Development Deals Example Partnership: Upfront Cash and/or Equity Purchase Milestone Payments Collaboration and License Agreement Partners: Biogen, Sage Jurisdiction: Global Products: Sage-217, Sage-324 Stage: Phase 3 Indications: PPD, MDD, essential tremor, other Upfron
Slide 16: Competitive Landscape
Company Program Status Ticker Market Cap Progress Gen 2 Pre-Clinical Enveric Public NASDAQ:ENVB $6.11M Biosciences Gen 3 Discovery Gen 1 Phase 3 Compass Public NASDAQ:CMPS $413.3M Pathways Gen 2 Pre-Clinical Gen 2 Phase 2 Cybin Inc. Public NYSE:CYBN $129.4M Gen 3 Pre-Clinical $73.6 Total funding – P
Slide 17: Value Inflection Points
Value Inflection Points EB373 File HREC for EB373 in Australia First patient dosed in Phase 1 clinical trial – EB373 Positive results from initial Phase 1 clinical trial for EB373 File IND for EB373 in US EVM301 Additional Notices of Allowance for EVM301 Lead candidate nomination for EVM301 Manufact
Slide 18: The Future of Neuroplastogen Medicine
The Future of Neuroplastogen Medicine Pipeline provides multiple shots on goal • Patented molecules can address multiple psychological indications Strong IP Portfolio • One patent and two patent Notices of Allowance with 10+ more anticipated • Large number of molecules expected to act as neuroplasto
Slide 19: Enveric.com
Nasdaqg:ENVB | EN VERT fentornecien~ Mental Health™ Mit BIOSCIENCES Enveric.com
Enveric Biosciences — Investor Presentation (August 2023) on 6ix